How to build anti-PD1 agonist antibodies

The checkpoint molecule PD1 is an attractive target for inflammatory diseases as it is specifically upregulated by activated immune cells. Therefore, activating its inhibitory function with agonists can potentially inhibit pathogenic effector cells without affecting PD1-negative immune cells. Although PD1-targeted monoclonal antibodies (mAbs) with anti-inflammatory activity have been reported, their mode of action is unknown. Now, a report in Science Immunology uncovers the crucial features that allow mAbs to induce inhibitory signalling via PD1.

留言 (0)

沒有登入
gif